This announcement contains
inside information
for the purposes of UK Market Abuse Regulation.
EKF Diagnostics Holdings
plc
("EKF" or
the "Company")
Notice of Results &
Investor Presentations
EKF Diagnostics Holdings
plc (AIM: EKF), the AIM-listed global
diagnostics business, will
announce its full year results for the year ended
31 December 2024, on Tuesday 25 March 2025.
Investor presentation
Julian Baines, Executive Chair, and
Stephen Young, CFO, will present the Company's results in two
separate events open to all investors. The same presentation will
be given at both events, which are being held at different times to
offer convenient options for those wishing to attend.
Two presentations will take place
on Tuesday 25 March 2025 at the following times, the
first will be held online via the Investor Meet Company platform
and the second will be held in-person in the City of London, full
details below:
1. Investor
Meet Company online presentation
EKF management will provide a live
online presentation relating to the final results via
Investor Meet Company at 4.15pm on Tuesday 25 March 2025. The
presentation is open to all existing and potential shareholders.
Questions can be submitted pre-event via your Investor Meet Company
dashboard up until 9am the day before the meeting or at any time
during the live presentation.
Investors can sign up to Investor
Meet Company for free and add to meet EKF via:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
A recording of the presentation, a
PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform
afterwards.
2.
In-person investor presentation
EKF management will provide an
in-person presentation relating to the Company's final results
at 5.30pm on Tuesday 25 March 2025, which is open to all existing
and potential shareholders. The Company welcomes investors to 75
King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm
start and will be followed by refreshments.
If you would like to attend, please
contact Walbrook PR on 020 7933 8780 or
email EKF@walbrookpr.com.
|
EKF
Diagnostics Holdings plc
|
www.ekfdiagnostics.com
|
|
Julian Baines, Executive Chair
/ Stephen Young, CFO
|
via Walbrook
PR
|
|
|
|
|
Singer Capital Markets (Nominated
Adviser & Broker)
|
Tel: +44
(0)20 7496 3000
|
|
Phil Davies / Oliver
Platts
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933 8780
or ekf@walbrookpr.com
|
|
Paul McManus / Alice
Woodings
|
Mob: +44
(0)7980 541 893 / +44 (0)7407 804
654
|
|
|
|
| |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global
diagnostics business focussed on:
|
●
|
Point-of-Care analysers in
the key areas of Hematology and Diabetes
|
|
●
|
Life Sciences services
provide specialist manufacture of enzymes and custom products for
use in diagnostic, food and industrial applications.
|
EKF has headquarters in Penarth
(near Cardiff) and operates five manufacturing sites across the US
and Germany, selling into over 120 countries world-wide.
